Springer Timothy A's Form 4 filing
Cartesian Therapeutics, Inc. (RNAC) · filed Dec 23, 2024
- Accession no.
- 0001453687-24-000147
- Filed
- Dec 23, 2024
- Trade date
- Dec 19-23, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market purchases total $965.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Springer Timothy ACIK 0001055624 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2024 | Common Stock | PPurchaseAcquired | +11,303 | $17.39F1 | +$196,559.17 | 8,467,009 | Direct | |
| Dec 19, 2024 | Common Stock | PPurchaseAcquired | +10,529 | $18.35F2 | +$193,207.15 | 8,477,538 | Direct | |
| Dec 19, 2024 | Common Stock | PPurchaseAcquired | +3,376 | $18.93F3 | +$63,907.68 | 8,480,914 | Direct | |
| Dec 20, 2024 | Common Stock | PPurchaseAcquired | +21,800 | $18.94F4 | +$412,892 | 8,502,714 | Direct | |
| Dec 23, 2024 | Common Stock | PPurchaseAcquired | +5,181 | $19.00F5 | +$98,439 | 8,507,895 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.81 to $17.7912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.82 to $18.8125. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.82 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.73 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.98 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.